Department of Women's Oncology at H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, USA.
Cancer Control. 2011 Jan;18(1):8-15. doi: 10.1177/107327481101800102.
DNA microarray technology is a powerful genomic tool that has the potential to elucidate the relationship between clinical features of cancers and their underlying biological alterations.
We performed a systemic search in PubMed and Medline databases for recently published articles. The search terms used included "genome-wide," "microarrays," "ovarian cancer," "prognosis, " "gene expression profiling, " "molecular marker, " and "molecular biomarker. "
Genome-wide expression profiling using DNA microarray technology has enhanced our understanding of the genes that influence ovarian cancer development, histopathologic subtype, progression, response to therapy, and overall survival.
Gene expression profiling has demonstrated its utility in ovarian cancer research. It is hoped that with technologic, statistical, and bioinformatic advances, the reliability and reproducibility of this technique will increase, spawning clinical applications that may enhance our understanding of the disease and our ability to care for patients in the future.
DNA 微阵列技术是一种强大的基因组工具,具有阐明癌症的临床特征与其潜在生物学改变之间关系的潜力。
我们在 PubMed 和 Medline 数据库中进行了系统性搜索,查找最近发表的文章。使用的搜索词包括“全基因组”、“微阵列”、“卵巢癌”、“预后”、“基因表达谱分析”、“分子标志物”和“分子生物标志物”。
使用 DNA 微阵列技术进行全基因组表达谱分析,增强了我们对影响卵巢癌发生、组织病理学亚型、进展、对治疗的反应和总体生存的基因的理解。
基因表达谱分析已证明在卵巢癌研究中的实用性。随着技术、统计和生物信息学的进步,该技术的可靠性和可重复性有望提高,从而产生临床应用,这可能会增强我们对疾病的理解,并提高我们未来为患者提供护理的能力。